Barclays PLC Buys 13,351 Shares of LivaNova PLC (NASDAQ:LIVN)

Barclays PLC boosted its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 406,769 shares of the company's stock after buying an additional 13,351 shares during the period. Barclays PLC owned approximately 0.75% of LivaNova worth $18,837,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in LIVN. Russell Investments Group Ltd. lifted its position in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after acquiring an additional 219 shares in the last quarter. Sterling Capital Management LLC boosted its position in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after buying an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division boosted its position in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after buying an additional 720 shares during the last quarter. Vestcor Inc bought a new stake in LivaNova during the fourth quarter worth $204,000. Finally, Optimize Financial Inc purchased a new stake in LivaNova in the 4th quarter valued at $208,000. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. The Goldman Sachs Group reduced their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. Needham & Company LLC restated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research note on Monday, March 17th. Stifel Nicolaus decreased their price target on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. StockNews.com raised LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 25th. Finally, Wolfe Research cut LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, LivaNova currently has an average rating of "Buy" and a consensus price target of $61.17.

LivaNova Stock Performance

Shares of LIVN traded up $0.98 during trading hours on Thursday, hitting $37.31. The company's stock had a trading volume of 357,622 shares, compared to its average volume of 625,268. The business has a 50 day simple moving average of $39.35 and a two-hundred day simple moving average of $46.39. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.03 billion, a price-to-earnings ratio of 88.83 and a beta of 0.90.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.